Intern – In Vitro Immunology at Abata Therapeutics

Rockville, Maryland, United States

Apply Now

Not SpecifiedCompensation

InternshipExperience Level

InternshipJob Type

UnknownVisa

BiotechnologyIndustries

Skills

Key technologies and capabilities for this role

Mammalian Cell CultureSterile TechniqueELISAMSD AssaysGraphPad PrismMicrosoft ExcelIn Vitro Immune AssaysCytokine Analysis

Questions & Answers

Common questions about this position

Is this internship remote or onsite?

The internship is onsite in Rockville, MD.

What are the time commitment and duration for this internship?

It requires 20+ hours per week for a duration of 3-6 months, with a start date as soon as possible.

What qualifications are required for this internship?

Candidates must be currently enrolled in a college program related to Immunology or Cell Biology, have completed introductory lab coursework in related fields, and show interest in mammalian cell culture and sterile technique.

What is the company culture like for this internship?

The environment is fast-paced and entrepreneurial, valuing enthusiastic, innovative, goal-oriented, flexible individuals who are skilled communicators and contribute to an exciting, fun, and inclusive workplace.

What makes a strong candidate for this internship?

Strong candidates are self-motivated problem-solvers with a drive for results, excellent communication and record-keeping skills, and strong interpersonal abilities to foster collaboration.

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free